HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
Heterocyclic compounds of general structure of Formula l are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of t...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
14.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Heterocyclic compounds of general structure of Formula l are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung,and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as dieases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of the compounds include (RS)-3-Cyclopropyl-2-{443-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxyl-propionic acid and (R)-1-(4'-{541-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yll-2-fluoro-biphenyl-4-ylycyclopropanecarboxylic acid.
Des composés hétérocycliques de structure générale de formule I sont décrits, qui sont des ligands de récepteur d'acide lysophosphatidique, qui sont utiles dans le traitement des maladies et des conditions dépendantes du récepteur de l'acide lysophosphatidique, y compris sans toutefois s'y limiter les maladies concernant la fibrose, par exemple, du coeur, du rein, du foie et du poumon, et la sclérodermie; les maladies inflammatoires, comme la néphropathie diabétique et la maladie intestinale inflammatoire; les maladies oculaires, comme celles concernant la dégénérescence rétinienne; et les maladies nerveuses, comme le prurit et la douleur. Des exemples non limitatifs des composés comprennent l'acide RS)-3-Cyclopropyl-2-{4-[3-méthyl-4-((R)-1-phényl-éthoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propinique et l'acide (R)-(4'(5[1-(2-Chloro-phényl)-éthoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphényl-4-yl)-cyclopropanecarboxylique. |
---|---|
Bibliography: | Application Number: CA20142906931 |